000304505 001__ 304505
000304505 005__ 20250914022700.0
000304505 0247_ $$2doi$$a10.2967/jnumed.124.268860
000304505 0247_ $$2pmid$$apmid:40935615
000304505 0247_ $$2ISSN$$a0097-9058
000304505 0247_ $$2ISSN$$a0022-3123
000304505 0247_ $$2ISSN$$a0161-5505
000304505 0247_ $$2ISSN$$a1535-5667
000304505 0247_ $$2ISSN$$a2159-662X
000304505 0247_ $$2altmetric$$aaltmetric:181365996
000304505 037__ $$aDKFZ-2025-01893
000304505 041__ $$aEnglish
000304505 082__ $$a610
000304505 1001_ $$aHosseini, Atefeh$$b0
000304505 245__ $$aHow Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.
000304505 260__ $$aNew York, NY$$bSoc.$$c2025
000304505 3367_ $$2DRIVER$$aarticle
000304505 3367_ $$2DataCite$$aOutput Types/Journal article
000304505 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1757681973_20211
000304505 3367_ $$2BibTeX$$aARTICLE
000304505 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304505 3367_ $$00$$2EndNote$$aJournal Article
000304505 500__ $$aepub
000304505 520__ $$aReactive fibrosis is a complex response to chronic myocardial insults, contributing to heart failure progression. Fibroblast activation protein inhibitor (FAPI) PET shows promise in distinguishing active from established fibrosis. Although antifibrotic therapies may improve left ventricular (LV) function in preclinical studies, their clinical application is limited by the lack of noninvasive imaging methods to assess fibrosis regression. This study investigates the potential of FAPI PET to track the therapeutic transition of activated fibroblast activation protein (FAP)-positive fibroblasts toward a FAP-negative phenotype. Methods: Mice were implanted with minipumps, infused with angiotensin-II/phenylephrine (Ang-II/PE) for 6 wk and scanned with 68Ga-FAPI-46 PET/CT longitudinally. Control mice received saline. 68Ga-FAPI-46 biodistribution studies were conducted at preselected time points, and FAPI uptake in the major organs was measured ex vivo. To assess the potential reversibility of the FAPI PET signal in the myocardium and liver, Ang-II/PE infusion was discontinued in a group of animals at 1 and 2 wk, respectively. LV structural and functional changes were assessed via echocardiography, tissue fibrosis via histology, and FAP expression via immunohistochemistry. Results: Significant 68Ga-FAPI-46 uptake in the myocardium of treated mice peaked at 1 wk. An increase of 68Ga-FAPI-46 uptake was also observed in the liver, peaking at 2 wk, and decreased significantly at 4 wk. The PET signal declined to an indiscernible level in the heart and liver early after Ang-II/PE withdrawal. Three weeks after the removal of the minipumps, the hearts of mice previously exposed to Ang-II/PE for 1 wk exhibited a significant reduction in fibrosis compared with mice that were sacrificed immediately after 1 wk of Ang-II/PE infusion, without the 3-wk recovery period. Coinjection with excess unlabeled FAPI-46 reduced uptake in the heart, liver, and kidneys. Despite an increase in LV wall thickness at 1 wk, the ejection fraction remained stable initially but dropped significantly by 4 wk. Conclusion: The rapid decline in PET signal after Ang-II/PE withdrawal shows that FAPI PET effectively visualizes dynamic changes in FAP expression, making it a valuable tool for quickly assessing treatment responses targeting activated fibroblasts. The cardiac FAPI signal precedes functional myocardial changes, indicating that FAPI PET could detect early fibrosis in cardiac remodeling leading to heart failure. FAPI PET may also visualize cardiac cirrhosis, a serious complication of cardiac disorders.
000304505 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304505 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304505 650_7 $$2Other$$aFAPI PET
000304505 650_7 $$2Other$$arapid therapy response monitoring
000304505 650_7 $$2Other$$asignal reversibility
000304505 7001_ $$aHaj-Yehia, Elias$$b1
000304505 7001_ $$aKorste, Sebastian$$b2
000304505 7001_ $$aKuzay, Yalcin$$b3
000304505 7001_ $$0P:(DE-He78)f3d58748e1cfc4f7f191b6719ec5b39e$$aTrajkovic-Arsic, Marija$$b4$$udkfz
000304505 7001_ $$aSettelmeier, Stephan$$b5
000304505 7001_ $$aCantore, Miriam$$b6
000304505 7001_ $$aFerenz, Katja B$$b7
000304505 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens T$$b8$$udkfz
000304505 7001_ $$aHerrmann, Ken$$b9
000304505 7001_ $$aRassaf, Tienush$$b10
000304505 7001_ $$aHendgen-Cotta, Ulrike$$b11
000304505 7001_ $$aWeber, Wolfgang A$$b12
000304505 7001_ $$aVarasteh, Zohreh$$b13
000304505 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.124.268860$$gp. jnumed.124.268860 -$$pnn$$tJournal of nuclear medicine$$vnn$$x0097-9058$$y2025
000304505 909CO $$ooai:inrepo02.dkfz.de:304505$$pVDB
000304505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f3d58748e1cfc4f7f191b6719ec5b39e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000304505 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304505 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304505 9141_ $$y2025
000304505 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000304505 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2025-01-01
000304505 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304505 980__ $$ajournal
000304505 980__ $$aVDB
000304505 980__ $$aI:(DE-He78)ED01-20160331
000304505 980__ $$aUNRESTRICTED